Product Images Vigabatrin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 17 images provide visual information about the product associated with Vigabatrin NDC 59651-366 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - vigabatrin fig1
This appears to be a graph displaying the percentage reduction in seizure frequency for different treatment groups. The treatments are referred to as Plcsbo, Tolday, aglday V68, and bgiday. The x-axis displays the percentage of patients in the treatment group and the y-axis shows the percent reduction in seizure frequency. The graph shows three groups with varying degrees of improvement, no change or worsening. No further context is available to interpret the origin, purpose, or nature of the data.*
Figure F - vigabatrin fig10
Figure G - vigabatrin fig11
Figure H - vigabatrin fig12
Figure I - vigabatrin fig13
Figure J - vigabatrin fig14
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (Packet) - vigabatrin fig15
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (50 Packets Carton) - vigabatrin fig16
This text is the description of Vigabatrin for Oral Solution. It includes directions for use, storage information, and a recommendation for dispensing the medication guide to each patient. The package contains 50 packets which are to be separately mixed with 0 mL of water and immediately administered. The package is not child-resistant and should be stored at controlled room temperature. The medication is manufactured by Aurobindo Pharma USA, Inc. and the provided code is APDRUGSI2016.*
Figure 2 - vigabatrin fig2
The text describes a figure labeled as Figure 2 that displays the percentage reduction in seizures in patients from baseline. The figure includes a chart with the percentage on the y-axis and the percentage of patients on the x-axis. The chart shows that some patients had a reduction of 100% while others showed no change or worsening. The caption indicates that a placebo was involved in the study.*
Figure3 - vigabatrin fig3
Oral Syringe Detail - vigabatrin fig4
This text seems to be a short phrase that doesn't provide enough context for generating a useful description. It is possible that this text describes an image or a document that has more information on "Oral syringe detail". Without any additional context, it is not possible to generate a meaningful description.*
Figure5 - vigabatrin fig5
Figure B - vigabatrin fig6
Figure C - vigabatrin fig7
Figure D - vigabatrin fig8
Figure E - vigabatrin fig9
Chemical Structure - vigabatrin str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.